FNDR-20123

Overview

FNDR-20123 is a safe, first-in-class, and orally active anti-malarial HDAC inhibitor with IC 50 s of 31 nM and 3 nM for Plasmodium and human HDAC , respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC 50 =41 nM) and sexual blood stage (IC 50 =190 nM for male gametocytes). FNDR-20123 inhibits HDAC1 , HDAC2 , HDAC3 , HDAC6 , and HDAC8 (IC 50 =25/29/2/11/282 nM, respectively.) and inhibits Class III HDAC isoforms at nanomolar concentrations.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-131708A
• CAS No.: 2641930-61-0
• Molecular Formula: C21H24ClN5O2
• Molecular Weight: 413.90
• Purity: 98.00%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (5.03 mM); Clear solution
• Availability: In-stock

Source

Original product source